Trial · NCT06622603
the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
NCT06622603, Phase 4, Recruiting, Seoul National University Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More. Trials, record NCT06622603. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06622603
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
- NCT number
- NCT06622603
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 59 participants, estimated
- Lead sponsor
- Seoul National University Hospital
- Conditions
- Gout, Uric Acid
- Interventions
- Febuxostat
- First posted
- 2024-10-02
- Last updated
- 2026-04-29
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of patients with serum urate levels <7.0 mg/dL | 6 months | The proportion of patients who maintain serum urate levels \<7.0 mg/dL at 6 months after taking febuxostat 20 mg once daily or after suspending urate-lowering agents |
| Secondary | The proportion of subjects with serum urate <7.0 mg/dL | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Serum urate levels | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Gout Impact Scale (GIS) score using the Korean version | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Patient's overall assessment of gout using a visual analog scale | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | EuroQol(EQ)-5D score | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Gout activity score (GAS) | 6 months and 12 months | GAS is calculated as (0.09 × last 12-month attacks) + \[1.01 × square root (serum uric acid)\] + \[0.34 × VAS patient\] + \[0.53 × ln (1 + tophi number)\] We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
| Secondary | Drug adherence | 6 months and 12 months | Adherence is defined as defined as taking 80% or more of the prescribed medication (using by the number of remaining pills). We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
| Secondary | Incidence rate of acute gouty arthritis | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
| Secondary | Swollen and tender joint counts of 66/68 joints | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers20
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06622603
GET https://conductscience.org/api/trials/v1/NCT06622603/registered